-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – GC-1109 in Anthrax
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. GC-1109 in Anthrax Drug Details: GC-1109 is under development for the prevention of anthrax. It...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – GC-101 in Metastatic Melanoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. GC-101 in Metastatic Melanoma Drug Details: GC-101 is under development for the treatment of gastrointestinal...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Codrituzumab in Metastatic Hepatocellular Carcinoma (HCC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Codrituzumab in Metastatic Hepatocellular Carcinoma (HCC) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Codrituzumab in Metastatic Hepatocellular Carcinoma (HCC) Drug Details: Codrituzumab (RG-7686,...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – ZD-100 in Resistant Hypertension
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ZD-100 in Resistant Hypertension report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ZD-100 in Resistant Hypertension Drug Details: ZD-100 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – MCLA-129 in Laryngeal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - MCLA-129 in Laryngeal Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. MCLA-129 in Laryngeal Cancer Drug Details: MCLA-129 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – MCLA-129 in Oropharyngeal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - MCLA-129 in Oropharyngeal Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. MCLA-129 in Oropharyngeal Cancer Drug Details: MCLA-129 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – LCB-84 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - LCB-84 in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. LCB-84 in Solid Tumor Drug Details: LCB-84 is under development for...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – RG-6115 in Triple-Negative Breast Cancer (TNBC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - RG-6115 in Triple-Negative Breast Cancer (TNBC) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. RG-6115 in Triple-Negative Breast Cancer (TNBC) Drug Details: RG-6115 (RO-7119929)...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – MCLA-129 in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - MCLA-129 in Non-Small Cell Lung Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. MCLA-129 in Non-Small Cell Lung Cancer Drug Details: MCLA-129 is...